Prophylactic vs Therapeutic Dosing in Fibrosis Models
Prophylactic vs therapeutic dosing in Bleomycin IPF, GAN MASH, and UUO fibrosis models. Lessons from Simtuzumab and Selonsertib clinical failures.
Is Your Efficacy Study Actually "Preventing" Disease?
"It Worked in Mice, But Failed in Clinic"
How many times has this refrain echoed through fibrosis drug development? The root cause often lies not in the compound itself, but in preclinical study design.
One of the most overlooked errors is the failure to distinguish between "Prophylactic" and "Therapeutic" dosing.
In the clinic, patients present with already-established disease. Yet in preclinical studies — remarkably — the majority still use "prophylactic" designs where treatment begins simultaneously with disease induction.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
The "Trap" of Prophylactic Dosing: Lessons from the Bleomycin Model
This problem is most starkly illustrated in the Bleomycin model of IPF (Idiopathic Pulmonary Fibrosis).
The bleomycin model progresses through two distinct phases:
Why Prophylactic Dosing "Lies"
- Intervening during the inflammatory phase: Day 0-7 dosing merely suppresses inflammation, not fibrosis. Anti-inflammatory drugs can be misidentified as "anti-fibrotic."
- Self-resolving model nature: Bleomycin-induced pulmonary fibrosis spontaneously improves after Day 28, making prophylactic results indistinguishable from natural recovery.
- Clinical disconnect: At the point of clinical dosing, IPF patients already have advanced fibrosis (Ashcroft score ≥5 equivalent). Day 0 prophylactic dosing does not reflect this clinical scenario at all.
A Startling Statistic
A systematic review by Moeller et al. (2008) found that of 240 bleomycin model drug efficacy studies published between 1980-2006, 222 (93%) used prophylactic designs — only 13 were therapeutic. Even in more recent surveys (2008-2019), over 60% of studies still employed prophylactic dosing only.
The "Therapeutic Dosing Window" Across Models
When should treatment begin to qualify as "therapeutic" in each fibrosis model?
| Model | Prophylactic (⚠️) | Therapeutic (✅) | Rationale |
|---|---|---|---|
| Bleomycin (IPF) | Day 0-7 | Day 7-14+ | After inflammatory phase = fibrotic phase |
| GAN Diet (MASH) | Concurrent with diet | After 24w diet, treat for 4-8w | After F2-F3 fibrosis is established |
| UUO (Renal Fibrosis) | Pre-surgery/Day 0 | Post-surgery Day 7-14+ | After interstitial fibrosis is established |
| CDAHFD (MASH) | Concurrent with diet | After 6w diet | After significant fibrosis appears |
Case Studies: Learning from Clinical Failures
Simtuzumab (LOXL2 Inhibitor) — Gilead, Discontinued 2016
Simtuzumab is an antibody targeting LOXL2, an enzyme involved in collagen cross-linking. Preclinical results showed promise for preventing and reversing fibrosis.
However, in the clinic:
- NASH Phase 2b: No significant difference vs. placebo in F3/F4 patients. All groups (including placebo) showed some collagen decrease, but drug groups showed no superiority.
- IPF Phase 2 (RAINIER trial): Terminated early for lack of efficacy.
Most strikingly, follow-up studies in humanized SCID mouse models revealed that Simtuzumab worsened pulmonary fibrosis in both preventative AND therapeutic settings — hydroxyproline levels increased, and it paradoxically promoted fibroblast-to-myofibroblast differentiation in a dose-dependent manner.
Selonsertib (ASK1 Inhibitor) — Gilead, Results Announced 2019
Selonsertib inhibits ASK1, a protein involved in oxidative stress responses.
- Phase 2: Small trials showed early signals of fibrosis improvement.
- Phase 3 (STELLAR-3/4): Large trials in F3 (STELLAR-3) and F4 (STELLAR-4) patients failed to meet primary endpoints (fibrosis improvement). No statistically significant difference from placebo.
The lesson is clear: "promising signals" in small Phase 2 trials can arise from insufficient placebo groups or statistical chance, leading to "regression to the truth" in larger Phase 3 studies.
Decision Tree: When Should You Start Dosing?
Conclusion: "When You Dose" Defines "What You Prove"
In preclinical study design, dosing timing is as critical as compound selection.
"Efficacy" demonstrated with prophylactic dosing does not guarantee clinical success. Rather, data showing effects against established fibrosis in a therapeutic setting is the true evidence that increases the Probability of Success (PoS) in clinical trials.
"Does this compound work against already-established fibrosis?" — Choosing a study design that answers this question is the shortest path to drug discovery success.
Related Articles
References
- Moeller A, et al. Int J Biochem Cell Biol. 2008. (Bleomycin model: prophylactic vs therapeutic systematic review)
- Jenkins RG, et al. Am J Respir Crit Care Med. 2017. (Preclinical IPF study design recommendations)
- Tølbøl KS, et al. World J Gastroenterol. 2018. (GAN DIO-NASH model)
- Harrison SA, et al. Gastroenterology. 2018. (Simtuzumab Phase 2b in NASH)
- Loomba R, et al. Hepatology. 2018. (Selonsertib Phase 2 in NASH)
- Harrison SA, et al. J Hepatol. 2020. (STELLAR-3/4 results)